Compass Therapeutics, Inc.
Moat Score — Compass Therapeutics, Inc.
Total Moat Score
8 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Nearly 100 issued patents and pending applications across its StitchMabs bispecific discovery platform and three lead programs, plus statistically significant Phase 2/3 data for tovecimig, but no approved product yet means commercial value of this IP is still unproven. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | No owned manufacturing and no scale economics; the company relies entirely on third-party CMOs and has no structural cost edge over larger, better-capitalized oncology competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Pre-revenue with no approved products, so there is no current pricing power; a future approval in a rare, underserved tumor type like biliary tract cancer could support premium orphan-like pricing, but this remains speculative. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Biopharmaceutical drug development and antibody therapeutics carry no network effects; value does not increase with the number of users or prescribers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | No approved product exists yet, so there are no entrenched prescriber or payer switching costs; any such dynamic could only emerge post-approval and would likely be modest relative to larger franchises. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Biliary tract cancer is a small, rare-disease market (~26,500 U.S. cases annually) that may not attract large pharma competition directly, giving a first/early mover some breathing room, but Compass's own scale (39 employees, no commercial infrastructure) remains far below what is needed to defend the position long term. |